United States - English - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride in 5% dextrose injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

United States - English - NLM (National Library of Medicine)

hainan poly pharm. co., ltd. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine

United States - English - NLM (National Library of Medicine)

slate run pharmaceuticals - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine injection, usp is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride is contraindic

United States - English - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risk of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine is contraindicated in patients with idiopath

Canada - English - Health Canada

sanofi canada, inc. - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - sympathomimetic (adrenergic) agents

Canada - English - Health Canada

novopharm limited - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

ivax pharmaceuticals incorporated - dobutamine (dobutamine hydrochloride) - solution - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Canada - English - Health Canada

sandoz canada incorporated - dobutamine (dobutamine hydrochloride) - liquid - 12.5mg - dobutamine (dobutamine hydrochloride) 12.5mg - selective beta 1-adrenergic agonists

Malta - English - Medicines Authority

wockhardt uk limited ash road north, wrexham, ll13 9uf, united kingdom - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy

Malta - English - Medicines Authority

cherubino limited delf building, sliema road, gzira, gzr 1637, malta - dobutamine - concentrate for solution for infusion - dobutamine 12.5 mg/ml - cardiac therapy